Isabel Álvarez

5.5k total citations
60 papers, 652 citations indexed

About

Isabel Álvarez is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Isabel Álvarez has authored 60 papers receiving a total of 652 indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Oncology, 30 papers in Cancer Research and 19 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Isabel Álvarez's work include Breast Cancer Treatment Studies (28 papers), HER2/EGFR in Cancer Research (21 papers) and Cancer Treatment and Pharmacology (18 papers). Isabel Álvarez is often cited by papers focused on Breast Cancer Treatment Studies (28 papers), HER2/EGFR in Cancer Research (21 papers) and Cancer Treatment and Pharmacology (18 papers). Isabel Álvarez collaborates with scholars based in Spain, United States and Switzerland. Isabel Álvarez's co-authors include C Redondo, D Boixeda, Miguel Ángel Seguí, Aňa Lluch, Laura García‐Estévez, Lennart Mucke, Xinxing Yu, Montserrat Muñoz-Mateu, Carlos Montalbán and C Bellas and has published in prestigious journals such as Neuron, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Isabel Álvarez

57 papers receiving 631 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Isabel Álvarez Spain 14 267 183 179 137 115 60 652
Yusha Liu United States 10 388 1.5× 193 1.1× 96 0.5× 158 1.2× 106 0.9× 40 784
Efraim H. Rosenberg Netherlands 15 235 0.9× 58 0.3× 163 0.9× 413 3.0× 214 1.9× 27 1.1k
Katsuyoshi Miyashita Japan 16 198 0.7× 126 0.7× 114 0.6× 523 3.8× 96 0.8× 47 1.0k
María E.R. García-Rendueles Spain 15 190 0.7× 96 0.5× 93 0.5× 309 2.3× 70 0.6× 19 799
Li-Ching Lin Taiwan 20 315 1.2× 153 0.8× 204 1.1× 393 2.9× 112 1.0× 27 890
Dariusz J. Jaskólski Poland 17 87 0.3× 105 0.6× 201 1.1× 286 2.1× 147 1.3× 96 962
Satoko Morohashi Japan 18 286 1.1× 161 0.9× 259 1.4× 403 2.9× 200 1.7× 65 978
Kenji Akazawa Japan 12 92 0.3× 90 0.5× 177 1.0× 64 0.5× 106 0.9× 21 691
Chunhua Xi China 13 259 1.0× 93 0.5× 93 0.5× 152 1.1× 87 0.8× 35 510
Ke Gong China 16 256 1.0× 130 0.7× 241 1.3× 579 4.2× 31 0.3× 39 1.0k

Countries citing papers authored by Isabel Álvarez

Since Specialization
Citations

This map shows the geographic impact of Isabel Álvarez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Isabel Álvarez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Isabel Álvarez more than expected).

Fields of papers citing papers by Isabel Álvarez

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Isabel Álvarez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Isabel Álvarez. The network helps show where Isabel Álvarez may publish in the future.

Co-authorship network of co-authors of Isabel Álvarez

This figure shows the co-authorship network connecting the top 25 collaborators of Isabel Álvarez. A scholar is included among the top collaborators of Isabel Álvarez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Isabel Álvarez. Isabel Álvarez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Elorriaga, Kepa, Luis Álvarez, Vanesa Quiroga, et al.. (2025). Molecular characterisation of the residual disease after neoadjuvant endocrine therapy in ER+/HER2- breast cancer uncovers biomarkers of tumour response. Translational Oncology. 57. 102407–102407.
2.
3.
Martínez-Jáñez, Noelia, Fernando Henao, Luís Manso, et al.. (2023). Abstract P4-01-28: PALBOSPAIN: OBSERVATIONAL ANALYSIS OF FIRST-LINE THERAPY WITH PALBOCICLIB IN PATIENTS WITH HR+/HER2- METASTATIC BREAST CANCER (MBC) IN REAL-LIFE CONDITIONS. Cancer Research. 83(5_Supplement). P4–1. 3 indexed citations
4.
Guerrero, Ángel, Miguel Gil‐Gil, Christoph Zielinski, et al.. (2023). Cyclin E cytoplasmatic isoform to predict outcome and benefit to capecitabine treatment in patients with HR+/HER2- metastatic breast cancer from the GEICAM/2013-02 PEARL study.. Journal of Clinical Oncology. 41(16_suppl). 1023–1023. 1 indexed citations
5.
López‐Tarruella, Sara, Raquel Andrés Conejero, M. Martín Jiménez, et al.. (2023). 114P Retrospective analysis to validate the CTS5 in patients from El Álamo IV registry and GEICAM adjuvant studies. ESMO Open. 8(1). 101338–101338. 1 indexed citations
6.
Castillo‐Lluva, Sonia, Nélida Salvador, Adrián Blanco‐Gómez, et al.. (2021). The Pseudokinase TRIB3 Negatively Regulates the HER2 Receptor Pathway and Is a Biomarker of Good Prognosis in Luminal Breast Cancer. Cancers. 13(21). 5307–5307. 10 indexed citations
7.
Ibarrondo, Oliver, et al.. (2021). Health care costs of breast, prostate, colorectal and lung cancer care by clinical stage and cost component. Gaceta Sanitaria. 36(3). 246–252. 12 indexed citations
8.
Ribelles, Nuria, Isabel Álvarez, Àngels Arcusa, et al.. (2021). Electronic health records and patient registries in medical oncology departments in Spain. Clinical & Translational Oncology. 23(10). 2099–2108. 3 indexed citations
9.
Chacón, José Ignacio, Luis de la Cruz‐Merino, Joaquín Gavilá Gregori, et al.. (2019). SEOM clinical guidelines in advanced and recurrent breast cancer (2018). Clinical & Translational Oncology. 21(1). 31–45. 13 indexed citations
10.
Templeton, Arnoud J., Álvaro Rodríguez-Lescure, A. Ruíz, et al.. (2018). Prognostic role for the derived neutrophil-to-lymphocyte ratio in early breast cancer: a GEICAM/9906 substudy. Clinical & Translational Oncology. 20(12). 1548–1556. 10 indexed citations
11.
Araujo, Angela M., et al.. (2017). New targets in triple negative breast cancer: Role of oncostatin M receptor pathway. Annals of Oncology. 28. v2–v2. 3 indexed citations
12.
Mar, Javier, et al.. (2016). Budget impact analysis of the 21-gene assay (Oncotype DX® breast cancer) for the breast cancer treatment in the Basque country. Annals of Oncology. 27. vi54–vi54. 1 indexed citations
13.
Llombart‐Cussac, Antonio, et al.. (2013). SEOM clinical guidelines for the management of metastatic breast cancer 2013. Clinical & Translational Oncology. 15(12). 1004–1010. 4 indexed citations
14.
Lluch, Aňa, Isabel Álvarez, Montserrat Muñoz-Mateu, et al.. (2013). Treatment innovations for metastatic breast cancer: Nanoparticle albumin-bound (NAB) technology targeted to tumors. Critical Reviews in Oncology/Hematology. 89(1). 62–72. 42 indexed citations
15.
Álvarez, Isabel, Ignacio Tusquets, Miguel Ángel Seguí, et al.. (2012). Finding the right dose of fulvestrant in breast cancer. Cancer Treatment Reviews. 39(2). 136–141. 4 indexed citations
16.
García‐Estévez, Laura, Isabel Álvarez, Miguel Ángel Seguí, et al.. (2010). Current perspectives of treatment of ductal carcinoma in situ. Cancer Treatment Reviews. 36(7). 507–517. 18 indexed citations
17.
Tusquets, Ignasi, Laura García‐Estévez, Encarna Adrover, et al.. (2010). Current controversies in the management of breast cancer. Clinical & Translational Oncology. 12(4). 278–286. 1 indexed citations
18.
García‐Estévez, Laura, Ignasi Tusquets, Isabel Álvarez, et al.. (2010). Supportive care for patients with early breast cancer. Clinical & Translational Oncology. 12(1). 32–42. 2 indexed citations
19.
Muñoz-Mateu, Montserrat, Laura García‐Estévez, Isabel Álvarez, et al.. (2008). Evaluation of international treatment guidelines and prognostic tests for the treatment of early breast cancer. Cancer Treatment Reviews. 34(8). 701–709. 16 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yusha Liu Breakdown of academic impact, for papers by Efraim H. Rosenberg Breakdown of academic impact, for papers by Katsuyoshi Miyashita Breakdown of academic impact, for papers by María E.R. García-Rendueles Breakdown of academic impact, for papers by Li-Ching Lin Breakdown of academic impact, for papers by Dariusz J. Jaskólski Breakdown of academic impact, for papers by Satoko Morohashi Breakdown of academic impact, for papers by Kenji Akazawa Breakdown of academic impact, for papers by Chunhua Xi Breakdown of academic impact, for papers by Ke Gong
Rankless by CCL
2026